よむ、つかう、まなぶ。
参考１ (62 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00332.html |
| 出典情報 | 「新型コロナウイルス感染症（COVID－19）診療の手引き・第7.1版」の周知について（3／31付 事務連絡）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
●新型コロナウイルス感染症（COVID-19） 診療の手引き・第 7.1 版 ●５ 薬物療法
◆引用・参考文献◆
・厚生労働省．現在開発中の新型コロナウイルス治療薬．2021.10.1.
・日本感染症学会．COVID-19 に対する薬物治療の考え方（第 13..1 版）
．2022.2.18.
・日本救急医学会・日本集中治療医学会．日本版敗血症診療ガイドライン 2020（J-SSCG2020）特別編，COVID-19 薬物療
法に関する Rapid/Living recommendations【第 4.2 版】2022.2.9.
・Bernal AJ, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 2021.
・Burwick RM, et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019.
Clin Infect Dis 2021.
・Chen P, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2020.
・Davis MR, et al. Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on
haemodialysis. J Antimicrob Chemother 2021.
・Diaz GA, et al. Remdesivir and mortality in patients with COVID-19. Clin Infect Dis 2021.
・FDA. Frequently Asked Questions on the Emergency Use Authorization for Actemra (Tocilizumab) for Treatment
of COVID-19. 24 June 2021.
・FDA. Frequently Asked Questions on the Emergency Use Authorization of Baricitinib for Treatment of COVID-19.
28 Jul 2021.
・Goldman JD, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020.
・Gottleib RL, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2021.
・Gupta A, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021.
・Hammond J, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 2022.
・Horby PW, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2020.
・Horby PW, et al. Tocilizumab in patients admitted to hospital with COVID-19（RECOVERY）: preliminary results of
a randomised, controlled, open-label, platform trial. Lancet 2021.
・Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2020.
・Kikuchi K, et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort
study. Ren Replace Ther 2021.
・Marconi VC, et al. Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from
the
randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial. medRixv 2021.
・Mozaffari E, et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of inhospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis 2021.
・NIH. Coronavirus diseases 2019（COVID-19）treatment guidelines. 1 Feb 2022.
・Nithya G, et al. A clinical study on the changing dynamics of disease severity, management strategies and
outcomes of COVID-19 in patients requiring haemodialysis. J Nephrol 2021.
・Pan H, et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med 2020.
・Salama C, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2020.
・Salvarani C, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with
COVID-19 pneumonia : a randomized clinical trial. JAMA Intern Med 2020.
・Shinkai M, et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen
therapy: A randomized, phase Ⅲ clinical trial. Infect Dis Ther 2021.
・Siemieniul RA, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and
network meta-analysis. BMJ 2021.
・Somers EC, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis
2020.
・Stone JH, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020.
・Takashita E, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med 2022.
・Weinreich DM, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med
2021.
・Weinreich DM, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med
2021.
・WHO. Therapeutics and COVID-19：living guidance. 14 Jan 2022.
62
◆引用・参考文献◆
・厚生労働省．現在開発中の新型コロナウイルス治療薬．2021.10.1.
・日本感染症学会．COVID-19 に対する薬物治療の考え方（第 13..1 版）
．2022.2.18.
・日本救急医学会・日本集中治療医学会．日本版敗血症診療ガイドライン 2020（J-SSCG2020）特別編，COVID-19 薬物療
法に関する Rapid/Living recommendations【第 4.2 版】2022.2.9.
・Bernal AJ, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med 2021.
・Burwick RM, et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019.
Clin Infect Dis 2021.
・Chen P, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med 2020.
・Davis MR, et al. Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on
haemodialysis. J Antimicrob Chemother 2021.
・Diaz GA, et al. Remdesivir and mortality in patients with COVID-19. Clin Infect Dis 2021.
・FDA. Frequently Asked Questions on the Emergency Use Authorization for Actemra (Tocilizumab) for Treatment
of COVID-19. 24 June 2021.
・FDA. Frequently Asked Questions on the Emergency Use Authorization of Baricitinib for Treatment of COVID-19.
28 Jul 2021.
・Goldman JD, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020.
・Gottleib RL, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med 2021.
・Gupta A, et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med 2021.
・Hammond J, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 2022.
・Horby PW, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med 2020.
・Horby PW, et al. Tocilizumab in patients admitted to hospital with COVID-19（RECOVERY）: preliminary results of
a randomised, controlled, open-label, platform trial. Lancet 2021.
・Kalil AC, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2020.
・Kikuchi K, et al. Survival and predictive factors in dialysis patients with COVID-19 in Japan: a nationwide cohort
study. Ren Replace Ther 2021.
・Marconi VC, et al. Efficacy and safety of baricitinib in patients with COVID-19 infection: Results from
the
randomised, double-blind, placebo-controlled, parallel-group COV-BARRIER phase 3 trial. medRixv 2021.
・Mozaffari E, et al. Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of inhospital all-cause mortality in a large multi-center observational cohort. Clin Infect Dis 2021.
・NIH. Coronavirus diseases 2019（COVID-19）treatment guidelines. 1 Feb 2022.
・Nithya G, et al. A clinical study on the changing dynamics of disease severity, management strategies and
outcomes of COVID-19 in patients requiring haemodialysis. J Nephrol 2021.
・Pan H, et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med 2020.
・Salama C, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2020.
・Salvarani C, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with
COVID-19 pneumonia : a randomized clinical trial. JAMA Intern Med 2020.
・Shinkai M, et al. Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen
therapy: A randomized, phase Ⅲ clinical trial. Infect Dis Ther 2021.
・Siemieniul RA, et al. Antibody and cellular therapies for treatment of covid-19: a living systematic review and
network meta-analysis. BMJ 2021.
・Somers EC, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis
2020.
・Stone JH, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020.
・Takashita E, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med 2022.
・Weinreich DM, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med
2021.
・Weinreich DM, et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N Engl J Med
2021.
・WHO. Therapeutics and COVID-19：living guidance. 14 Jan 2022.
62